Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/27/2786530/0/en/Anaptys-Expands-Immune-Cell-Modulator-Pipeline-with-Exclusive-License-to-BDCA2-Modulator-Antibody-Portfolio-from-Centessa-Pharmaceuticals.html

SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclusive license agreement for Centessa Pharmaceuticals’ (NASDAQ:CNTA) blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases. Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.

Read more at globenewswire.com

Related news for (ANAB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.